Location: Vacaville, California
Relocation assistance is available for eligible candidates and their families, if needed.
This is a fully site‑based role. Working together in person supports close, real‑time collaboration and the technical precision needed to manufacture medicines to the highest quality and safety standards.
Reporting to the E2E Program Lead, the End-to-End Project Lead for 11*12k / 8*25k is responsible for planning, managing and delivering the design, construction, commissioning and validation of the existing asset modifications in order to build product-agnostic capabilities for the Vacaville site, ensuring all tech transfers and overall large, complex projects pertaining to the respective asset. The Asset E2E lead has the ownership of the cost, scope and schedule of the projects to achieve their business goals. In line with their strategic, technical and project management responsibilities, the E2E Lead leads all the project functions.
The full-time base annual salary for this position is expected to range between $181,500 to $302,000. In addition, below you will find a comprehensive summary of the benefits package we offer:
At Lonza, our people are our greatest strength. With 30+ sites across five continents, our globally connected teams work together every day to manufacture the medicines of tomorrow. Our core values of Collaboration, Accountability, Excellence, Passion and Integrity reflect who we are and how we work together. Everyone’s ideas, big or small, have the potential to improve millions of lives, and that’s the kind of work we want you to be part of.
Innovation thrives when people from all backgrounds bring their unique perspectives to the table. At Lonza, we offer equal employment opportunities to all qualified applicants regardless of race, religion, color, national origin, sex, sexual orientation, gender identity, age, disability, veteran status, or any other characteristic protected by law.
Ready to shape the future of life sciences? Apply now.

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow.
Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs.
For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.